228 related articles for article (PubMed ID: 26274780)
41. Discovery of small molecule inhibitors that interact with γ-tubulin.
Friesen DE; Barakat KH; Semenchenko V; Perez-Pineiro R; Fenske BW; Mane J; Wishart DS; Tuszynski JA
Chem Biol Drug Des; 2012 May; 79(5):639-52. PubMed ID: 22268380
[TBL] [Abstract][Full Text] [Related]
42. Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes.
Flori L; Brogi S; Sirous H; Calderone V
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108741
[TBL] [Abstract][Full Text] [Related]
43. Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol.
Pradhan M; Suri C; Choudhary S; Naik PK; Lopus M
J Biomol Struct Dyn; 2018 Jan; 36(1):195-208. PubMed ID: 27960611
[TBL] [Abstract][Full Text] [Related]
44. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
45. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.
Kumbhar BV; Borogaon A; Panda D; Kunwar A
PLoS One; 2016; 11(5):e0156048. PubMed ID: 27227832
[TBL] [Abstract][Full Text] [Related]
46. Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
Porcù E; Sipos A; Basso G; Hamel E; Bai R; Stempfer V; Udvardy A; Bényei AC; Schmidhammer H; Antus S; Viola G
Eur J Med Chem; 2014 Sep; 84():476-90. PubMed ID: 25050880
[TBL] [Abstract][Full Text] [Related]
47. Discovery of noscapine derivatives as potential β-tubulin inhibitors.
Nemati F; Salehi P; Bararjanian M; Hadian N; Mohebbi M; Lauro G; Ruggiero D; Terracciano S; Bifulco G; Bruno I
Bioorg Med Chem Lett; 2020 Oct; 30(20):127489. PubMed ID: 32784088
[TBL] [Abstract][Full Text] [Related]
48. Imidazo[2,1-
Nagireddy PKR; Kommalapati VK; Siva Krishna V; Sriram D; Tangutur AD; Kantevari S
ACS Omega; 2019 Nov; 4(21):19382-19398. PubMed ID: 31763563
[TBL] [Abstract][Full Text] [Related]
49. Stabilization of microtubules by taxane diterpenoids: insight from docking and MD simulations.
Yadava U; Gupta H; Roychoudhury M
J Biol Phys; 2015 Mar; 41(2):117-33. PubMed ID: 25542396
[TBL] [Abstract][Full Text] [Related]
50. Targeting dormant phenotype acquired mycobacteria using natural products by exploring its important targets:
Sharma S; Chikhale R; Shinde N; Khan AM; Gupta VK
Front Cell Infect Microbiol; 2023; 13():1111997. PubMed ID: 37033483
[TBL] [Abstract][Full Text] [Related]
51. Assessing the performance of docking, FEP, and MM/GBSA methods on a series of KLK6 inhibitors.
Lima Silva WJ; Ferreira de Freitas R
J Comput Aided Mol Des; 2023 Sep; 37(9):407-418. PubMed ID: 37378817
[TBL] [Abstract][Full Text] [Related]
52. Copper(I) mediated facile synthesis of potent tubulin polymerization inhibitor, 9-amino-α-noscapine from natural α-noscapine.
Manchukonda NK; Sridhar B; Naik PK; Joshi HC; Kantevari S
Bioorg Med Chem Lett; 2012 Apr; 22(8):2983-7. PubMed ID: 22425569
[TBL] [Abstract][Full Text] [Related]
53. Integrating docking and molecular dynamics approaches for a series of proline-based 2,5-diketopiperazines as novel αβ-tubulin inhibitors.
Fani N; Bordbar AK; Ghayeb Y; Sepehri S
J Biomol Struct Dyn; 2015; 33(10):2285-95. PubMed ID: 25616934
[TBL] [Abstract][Full Text] [Related]
54. In vitro characterization and molecular dynamic simulation of shikonin as a tubulin-targeted anticancer agent.
Radha G; Naik PK; Lopus M
Comput Biol Med; 2022 Aug; 147():105789. PubMed ID: 35797892
[TBL] [Abstract][Full Text] [Related]
55. Dynamics simulation and in vitro studies of betulinic acid derivative with liver X receptor.
Yu P; Cao W; Wang Y
J Biomol Struct Dyn; 2023 Jul; ():1-10. PubMed ID: 37498160
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Mishra RC; Gundala SR; Karna P; Lopus M; Gupta KK; Nagaraju M; Hamelberg D; Tandon V; Panda D; Reid MD; Aneja R
Bioorg Med Chem Lett; 2015; 25(10):2133-40. PubMed ID: 25891106
[TBL] [Abstract][Full Text] [Related]
57. Exploration of the binding mode between (-)-zampanolide and tubulin using docking and molecular dynamics simulation.
Liao SY; Mo GQ; Chen JC; Zheng KC
J Mol Model; 2014 Feb; 20(2):2070. PubMed ID: 24478043
[TBL] [Abstract][Full Text] [Related]
58. Experimental and computational study of the interaction of novel colchicinoids with a recombinant human αI/βI-tubulin heterodimer.
Mane JY; Semenchenko V; Perez-Pineiro R; Winter P; Wishart D; Tuszynski JA
Chem Biol Drug Des; 2013 Jul; 82(1):60-70. PubMed ID: 23480279
[TBL] [Abstract][Full Text] [Related]
59. Development of 9-(
Pragyandipta P; Naik MR; Bastia B; Naik PK
3 Biotech; 2023 Feb; 13(2):38. PubMed ID: 36636578
[TBL] [Abstract][Full Text] [Related]
60. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
Hassanzadeh M; Bagherzadeh K; Amanlou M
J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
